Abstract
Hemopoietic stem cell transplantation (SCT) with fully ablative conditioning is associated with an age-related increase in treatment-related mortality. It is therefore particularly unsuited to older individuals, who are most at risk of developing acute myeloid leukemia (AML). Reduced-intensity SCT (RISCT) may be of value in this group. We report 17 consecutive patients with high-risk AML whose median age was 58 years and who received stem cells from HLA-matched siblings (n = 5), or alternative donors (n = 12). We used lymphodepleting antibodies as a part of the reduced-intensity conditioning regimen to limit the risk of graft rejection and graft-versus-host disease (GVHD). All patients engrafted. One patient developed severe fatal GVHD, and two patients died of infection. At a median follow-up of 861 days (372 -1957 days), seven patients are alive in remission, which includes two patients treated in relapse and five patients who lacked an MHC identical sibling donor.
Original language | English (US) |
---|---|
Pages (from-to) | 547-552 |
Number of pages | 6 |
Journal | Bone Marrow Transplantation |
Volume | 37 |
Issue number | 6 |
DOIs | |
State | Published - Mar 2006 |
Keywords
- Alemtuzumab
- AML
- Elderly
- Intensity
- Reduced
- Transplantation
ASJC Scopus subject areas
- Hematology
- Transplantation